BCL-X(L) PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS(G12C)-mutated cancers

KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent inhibitor of KRAS(G12C), was recently approved for the treatment of KRAS(G12C)-mutated non-small cell lung cancer (NSCLC). However, the efficacy of sotorasib and other KRAS(G12C) inhibitors is limited by intrinsic r...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Sajid, Wiegand, Janet, Zhang, Peiyi, Hu, Wanyi, Thummuri, Dinesh, Budamagunta, Vivekananda, Hua, Nan, Jin, Lingtao, Allegra, Carmen J., Kopetz, Scott E., Zajac-Kaye, Maria, Kaye, Frederic J., Zheng, Guangrong, Zhou, Daohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905794/
https://www.ncbi.nlm.nih.gov/pubmed/35260176
http://dx.doi.org/10.1186/s13045-022-01241-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905794/
https://www.ncbi.nlm.nih.gov/pubmed/35260176
http://dx.doi.org/10.1186/s13045-022-01241-3

Ejemplares similares